Get the Stockscreener App
17.55
0.80%
0.14
After Hours:
17.55
Dyne Therapeutics Inc stock is traded at $17.55, with a volume of 1.04M.
It is up +0.80% in the last 24 hours and down -3.20% over the past month.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
See More
Previous Close:
$17.41
Open:
$17.465
24h Volume:
1.04M
Relative Volume:
0.50
Market Cap:
$2.90B
Revenue:
-
Net Income/Loss:
$-446.21M
P/E Ratio:
-4.9529
EPS:
-3.5434
Net Cash Flow:
$-423.92M
1W Performance:
-7.14%
1M Performance:
-3.20%
6M Performance:
-22.28%
1Y Performance:
+48.85%
1-Day Range:
$17.29
$17.91
1-Week Range:
$17.29
$19.48
52-Week Range:
$8.06
$25.00
Dyne Therapeutics Inc Stock (DYN) Company Profile
Name
Dyne Therapeutics Inc
Sector
Industry
Phone
(781) 786-8230
Address
1560 TRAPELO ROAD, WALTHAM
Compare DYN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
17.55 | 3.00B | 0 | -446.21M | -423.92M | -3.5434 |
VRTX
Vertex Pharmaceuticals Inc
|
427.38 | 109.41B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
707.06 | 76.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
781.72 | 48.20B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
309.49 | 40.31B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
295.27 | 33.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-10-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-25-25 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jun-24-25 | Initiated | Bernstein | Mkt Perform |
| Jun-11-25 | Resumed | Raymond James | Outperform |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-29-25 | Initiated | Evercore ISI | Outperform |
| Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-13-24 | Initiated | Robert W. Baird | Outperform |
| Nov-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-24 | Downgrade | JP Morgan | Overweight → Neutral |
| May-21-24 | Reiterated | Chardan Capital Markets | Buy |
| Apr-30-24 | Initiated | Morgan Stanley | Overweight |
| Feb-20-24 | Initiated | H.C. Wainwright | Buy |
| Feb-27-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Feb-15-23 | Initiated | Oppenheimer | Outperform |
| Jan-26-23 | Initiated | Guggenheim | Buy |
| Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-22 | Initiated | Raymond James | Outperform |
| Oct-12-20 | Initiated | JP Morgan | Overweight |
| Oct-12-20 | Initiated | Jefferies | Buy |
| Oct-12-20 | Initiated | Piper Sandler | Overweight |
| Oct-12-20 | Initiated | Stifel | Buy |
View All
Dyne Therapeutics Inc Stock (DYN) Latest News
Dyne therapeutics director Jason Rhodes sells $4.18m in stock - Investing.com
Atlas Venture funds tied to Dyne (DYN) director sell 227,337 shares - Stock Titan
MSN Money - MSN
Could Dyne Therapeutics (DYN) Turn Its FORCE Platform Into a Broader Neurology Franchise? - simplywall.st
Dyne Therapeutics earnings up next: DMD launch path in focus By Investing.com - Investing.com India
Dyne Therapeutics earnings up next: DMD launch path in focus - Investing.com
Facioscapulohumeral Muscular Dystrophy Market: Pharma Pipeline Fuels Rapid Expansion – DelveInsight | Dyne Therapeutics, miRecule, Avidity Biosciences, aTyr Pharma, Fulcrum Therapeutics - Barchart
Facioscapulohumeral Muscular Dystrophy Market: Pharma - openPR.com
DYN SEC FilingsDyne Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Director at Dyne Therapeutics (DYN) makes bona fide gift of 53,625 shares - Stock Titan
Dyne Therapeutics Insider Sold Shares Worth $7,101,120, According to a Recent SEC Filing - marketscreener.com
Dyne therapeutics director Jason Rhodes sells $7.1m in stock By Investing.com - Investing.com South Africa
Dyne Therapeutics(DYN.US) Director Sells US$7.1 Million in Common Stock - Moomoo
Dyne therapeutics director Jason Rhodes sells $7.1m in stock - Investing.com
[Form 4] Dyne Therapeutics, Inc. Insider Trading Activity - Stock Titan
Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting - The Manila Times
[144] Dyne Therapeutics, Inc. SEC Filing - Stock Titan
Dyne Therapeutics Announces Upcoming Presentation - GlobeNewswire
Dyne Therapeutics (DYN) Stifel 2026 Virtual CNS Forum Summary - Quartr
Dyne Therapeutics (DYN) Proxy filing Summary - Quartr
Dyne Therapeutics (DYN) TD Cowen 46th Annual Health Care Conference Summary - Quartr
Dyne Therapeutics director Kersten sells $219k in company stock - Investing.com
Dyne Therapeutics director Kersten sells $219k in company stock By Investing.com - Investing.com India
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 - Investing News Network
[ARS] Dyne Therapeutics, Inc. SEC Filing - Stock Titan
Director-affiliated fund trims Dyne Therapeutics (DYN) stake in 10b5-1 sales - Stock Titan
Dyne Therapeutics (NASDAQ: DYN) sets 2026 virtual meeting, share increase vote - Stock Titan
Dyne used stock awards to hire 18 employees, covering 423,000 shares - Stock Titan
Jason Rhodes Sells 274,297 Shares of Dyne Therapeutics (NASDAQ:DYN) Stock - MarketBeat
Dyne Therapeutics (NASDAQ:DYN) Director Jason Rhodes Sells 272,049 Shares of Stock - MarketBeat
Dyne therapeutics director Jason Rhodes sells $16.48m in shares By Investing.com - Investing.com South Africa
Dyne Therapeutics(DYN.US) Director Sells US$16.48 Million in Common Stock - Moomoo
Atlas Venture funds sell Dyne (DYN) shares under 10b5-1 plan - Stock Titan
Dyne therapeutics director Dirk Kersten sells $6.8m in shares By Investing.com - Investing.com Australia
Dyne therapeutics director Dirk Kersten sells $6.8m in shares - Investing.com UK
DYN (Nasdaq) Form 144: Atlas Venture groups report proposed sales totaling tens of thousands of shares - Stock Titan
Atlas Venture affiliates sell shares of DYN (Nasdaq: DYN) in Rule 144 notices - Stock Titan
Atlas Venture sells DYN stock (Nasdaq: DYN) — 142,571-share entry listed - Stock Titan
Atlas Venture entities sell DYN shares (NASDAQ: DYN) under Form 144 disclosure - Stock Titan
Director-linked fund trims 337K Dyne Therapeutics (DYN) shares under 10b5-1 plan - Stock Titan
H.C. Wainwright Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Dyne Therapeutics: De-Risked DMD Opportunity, Pivotal DM1 Readout, and Emerging M&A Appeal Support Buy Rating - TipRanks
H.C. Wainwright reiterates Dyne Therapeutics stock rating at buy By Investing.com - Investing.com Canada
Dyne Therapeutics Inc Stock (DYN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):